Shi Zhiyuan, Zheng Jianzhong, Tang Wenbin, Bai Yang, Zhang Lei, Xuan Zuodong, Sun Huimin, Shao Chen
Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
School of Public Health, Xiamen Univerisity, Xiamen, China.
Front Chem. 2022 Mar 24;10:868630. doi: 10.3389/fchem.2022.868630. eCollection 2022.
Patient outcomes from the current clinical cancer therapy remain still far from satisfactory. However, in recent years, several biomedical discoveries and nanotechnological innovations have been made, so there is an impetus to combine these with conventional treatments to improve patient experience and disease prognosis. Ferroptosis, a term first coined in 2012, is an iron-dependent regulated cell death (RCD) based on the production of reactive oxygen species (ROS) and the consequent oxidization of polyunsaturated fatty acids (PUFAs). Many nanomaterials that can induce ferroptosis have been explored for applications in cancer therapy. In this review, we summarize the recent developments in ferroptosis-based nanomaterials for cancer therapy and discuss the future of ferroptosis, nanomedicine, and cancer therapy.
当前临床癌症治疗的患者预后仍远不尽人意。然而,近年来已有多项生物医学发现和纳米技术创新成果,因此有动力将这些与传统治疗方法相结合,以改善患者体验和疾病预后。铁死亡这一术语于2012年首次提出,是一种基于活性氧(ROS)生成以及多不饱和脂肪酸(PUFA)随之发生氧化的铁依赖性调节性细胞死亡(RCD)。许多可诱导铁死亡的纳米材料已被探索用于癌症治疗。在本综述中,我们总结了基于铁死亡的纳米材料在癌症治疗方面的最新进展,并讨论了铁死亡、纳米医学和癌症治疗的未来。